Bausch Lomb (BLCO) Q2 Revenue Rises 5%

Bausch + Lomb (NYSE:BLCO), a global eye health company known for its contact lenses, surgical devices, and eye pharmaceuticals, released results for the second quarter of fiscal 2025 on July 30, 2025. The main headline from the release is GAAP revenue growth of 5% year over year to $1.278 billion, beating analyst expectations by $18 million. Adjusted earnings per share (EPS) (non-GAAP) reached $0.07, beating the consensus estimate by $0.01 but falling short of last year's figure of $0.13. Top line growth and a narrowed net loss (GAAP) reflect some improvement, Margin pressure and a declining Pharmaceuticals segment weighed on overall profitability. The period showed strength in Vision Care, especially consumer and contact lens brands, offset by softer results in Pharmaceuticals and continued cost pressures. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Bausch + Lomb is a long-established company specializing in products for eye health, including contact lenses, over-the-counter (OTC) consumer eye care brands, prescription pharmaceuticals, and surgical devices. Its operations span three primary business segments: Vision Care, Surgical, and Pharmaceuticals.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool